Valeant's (VRX) Buy Rating Affirmed at BofA/Merrill Lynch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Citron Research to Discuss Valeant Pharma (VRX) at 12:30PM on Bloomberg
October 22, 2015 10:45 AM EDTCitron Research said it will be on Bloomberg TV at 12:30PM ET to discuss Valeant Pharma (NYSE: VRX) which follows yesterday's scathing report and drastic sell-off.
Bloomberg's live feed can be found here:... More
Valeant Pharma (VRX) Resumes Free-Fall; Down 15%
October 22, 2015 9:44 AM EDTValeant Pharma (NYSE: VRX) is back testing the $100 level again. Shares down 15% currently.
Today's BMO Capital downgrade, highlighted earlier, is certainly not helping.
... MoreDeutsche Bank 'Remains Cautious' on Valeant (VRX); Analyst Maintains Hold Rating
October 22, 2015 9:37 AM EDTDeutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $204. Analyst Gregg Gilbert said he remains cautious on the stock given uncertainties related to the drug pricing, its specialty pharmacy distribution model, and related government inquiries.
Gilbert explained, "VRX shares have been under significant pressure, most recently following allegations related to its specialty pharmacy distribution model. While it is difficult to predict how more conservative pricing behavior and other potential changes could affect revenue growth, we thought it would be helpful to look at... More
BMO Capital Downgrades Valeant Pharmaceuticals (VRX) to Market Perform; Cannot Defend the Specialty Pharmacy Structure
October 22, 2015 7:00 AM EDTBMO Capital downgraded Valeant Pharmaceuticals (NYSE: VRX) from Outperform to Market Perform with a price target of $141.00, saying they cannot defend the specialty pharmacy structure.
Analyst Alex Arfaei commented, "Based on our understanding, ~10% of Valeants revenues come from specialty pharmacies. While other companies also use specialty pharmacies, the structure of Valeants network seems different. In... More
